RxDoctor Payments DataLook up a doctor →

Jeffrey Feldman, MD

Nephrology · Union, NJNPI 1124081336

Payments from drug & device makers

$314,748in general payments, 2019–2025

Across 1,421 payments — averaging $221.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$174K
  • Lilly USA, LLC$42K
  • Boehringer Ingelheim$32K
  • AstraZeneca$27K
  • Johnson & Johnson$16K
  • GSK$8K
  • plus $16K from 42 others

What the payments were for

  • Consulting fees$16,3815%
  • Speaking & faculty fees$241,88277%
  • Travel & lodging$26,1748%
  • Food & beverage$29,7609%
  • Education$5520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314,748 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$152,790
Medicare patients
225
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone782$1,071,998
OzempicSemaglutide423$615,862
JardianceEmpagliflozin487$607,597
MounjaroTirzepatide287$443,887
RayaldeeCalcifediol173$273,911
FarxigaDapagliflozin Propanediol210$247,272
TrulicityDulaglutide106$151,384
VeltassaPatiromer Calcium Sorbitex100$137,261
XareltoRivaroxaban89$92,587
EntrestoSacubitril/Valsartan62$89,327
LokelmaSodium Zirconium Cyclosilicate76$66,391
EliquisApixaban55$58,743
VelphoroSucroferric Oxyhydroxide23$53,097
Repatha SureclickEvolocumab47$50,004
BiktarvyBictegrav/Emtricit/Tenofov Ala13$47,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$174,146$1,071,998782 claims
Novo NordiskOzempic, Rybelsus$2,570$635,976434 claims
Boehringer IngelheimJardiance$31,835$607,597487 claims
Lilly USA, LLCMounjaro, Trulicity$41,644$595,271393 claims
AstraZenecaFarxiga, Lokelma$26,973$313,663286 claims
OPKO Pharmaceuticals, LLCRayaldee$819$273,911173 claims
Johnson & JohnsonXarelto$16,186$92,58789 claims
NovartisEntresto$1,635$89,32762 claims
PfizerEliquis, Retacrit$12$84,50180 claims
Fresenius USA Marketing, Inc.Velphoro$285$53,09723 claims
Akebia Therapeutics IncAuryxia$165$42,95726 claims
AbbVieCreon$41$27,45823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →